Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.

Koji YadaK NogamiM TakeyamaK OgiwaraH WakabayashiM Shima

Published in: Journal of thrombosis and haemostasis : JTH (2015)

These results indicated that the P1809L mutation in A3 induced the conformational change in the FVIII molecule that hampered antigenic determinant(s) located in the C2 domain and might result in the inhibitor development.

Keyphrases

bone marrow
stem cell transplantation
high glucose
diabetic rats
case report
signaling pathway
molecular dynamics
molecular dynamics simulations
single molecule
cell therapy
drug induced
anti inflammatory
hematopoietic stem cell
low dose
oxidative stress
platelet rich plasma
stem cells
endothelial cells